Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07102576 · ClinicalTrials.gov registry record · Phase 1
MDMA-Assisted Therapy for Mental Healthcare Providers
A Phase 1 study of Mental Wellbeing, sponsored by Rachel Yehuda.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07102576: Recruiting Phase 1 study of Mental Wellbeing, sponsored by Rachel Yehuda.
NCT07102576 is a Phase 1 study of Mental Wellbeing that is actively recruiting participants, run by Rachel Yehuda. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07102576, a Phase 1 study of Mental Wellbeing, is actively recruiting participants, sponsored by Rachel Yehuda.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1, open-label study to assess changes in mental well-being following MDMA administration within a therapeutic setting, in mental health providers who are in training to become MDMA assisted therapists. Secondary outcome measures will examine the effects on provider burnout, provider self-efficacy, mood, self-compassion, quality of life, and other psychological factors. Participants will work with a co-therapy pair as they engage in a preparatory session, one experimental session with MDMA, and an integration session the following day.
Primary Outcome
The MHC-SF is a self-report measure consisting of 14 questions rated for the frequency at which they are experienced, on a scale from "0-never" to "5-every day" within the past month. The MHC-SF is a shortened version of the Mental Health Continuum Long Form (MHC-LF), a 40-item measure which was developed to assess emotional, social, and psychological well-being, a three factor structure validated in national and international populations. The MHC-SF was developed using a subset of items from th
Conditions Studied
Interventions
- DRUG MDMA Hydrochloride
Study Locations (1)
New York
- The Parsons Research Center for Psychedelic Healing - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01 |
| Est. Completion | 2029-12-21 |
| Phase | Phase 1 |
What NCT07102576 shows while recruiting
NCT07102576 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Mental Wellbeing appearing as the primary indexed condition, and to 1 intervention - of which MDMA Hydrochloride is the first listed.
NCT07102576 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07102576 about?
NCT07102576 is a clinical study titled "MDMA-Assisted Therapy for Mental Healthcare Providers". This is a phase 1, open-label study to assess changes in mental well-being following MDMA administration within a therapeutic setting, in mental health providers who are in training to become MDMA assisted therapists. Secondary outcome measures will examine the effects on provider burnout, provider ...
What is the current status of trial NCT07102576?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-01. Estimated completion is 2029-12-21.
What conditions does trial NCT07102576 study?
This clinical trial studies the following conditions: Mental Wellbeing.
What interventions are being tested in trial NCT07102576?
The interventions under investigation include: MDMA Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT07102576?
This trial is sponsored by Rachel Yehuda, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07102576 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mental Wellbeing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07102576's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia